Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1B | P47901 | 19/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6517780 | 0.97 | AVPR1B (0.49) | AVPR1BCYP3A4ALDH1A1 | |
| SCHEMBL6519596 | 0.95 | AVPR1B (0.47) | AVPR1BCYP3A4ALDH1A1 | |
| SCHEMBL6520690 | 0.94 | AVPR1B (0.48) | AVPR1BCYP3A4ALDH1A1 | |
| SCHEMBL6517380 | 0.94 | AVPR1B (0.49) | AVPR1BCYP3A4ALDH1A1 | |
| SCHEMBL3228806 | 0.94 | AVPR1B (0.43) | AVPR1BCYP3A4ALDH1A1 | |
| SCHEMBL6517560 | 0.93 | AVPR1B (0.47) | AVPR1BCYP3A4ALDH1A1 | |
| SCHEMBL6524340 | 0.93 | AVPR1B (0.47) | AVPR1BCYP3A4ALDH1A1 | |
| SCHEMBL6519098 | 0.93 | AVPR1B (0.48) | AVPR1BCYP3A4ALDH1A1 | |
| SCHEMBL6520717 | 0.93 | AVPR1B (0.50) | AVPR1BCYP3A4 | |
| SCHEMBL6517784 | 0.93 | AVPR1B (0.49) | AVPR1BCYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703774-B2 | Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-04-22 | — | — | US | claimed |
| US-20160362394-A1 | CARBAMATE-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT DISEASES | ABBVIE DEUTSCHLAND (DE) | 2016-12-15 | — | — | US | disclosed |
| US-9422264-B2 | Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-08-23 | — | — | US | disclosed |
| US-20140315914-A1 | CARBAMATE-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT DISEASES | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-10-23 | — | — | US | disclosed |
| US-8703774-B2 | Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-04-22 | — | — | US | disclosed |
| US-20110065720-A1 | CARBAMATE-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT DISEASES | ABOTT GMBH & CO KG (DE) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362394-A1 | CARBAMATE-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT DISEASES | AVPR2, AVPR1B, AVPR1A | AVPR1B 2/4885CYP3A4 3335/4885ALDH1A1 3653/4885 |
| US-20140315914-A1 | CARBAMATE-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT DISEASES | AVPR2, AVPR1B, AVPR1A | AVPR1B 2/4885CYP3A4 3335/4885ALDH1A1 3653/4885 |
| US-20110065720-A1 | CARBAMATE-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT DISEASES | AVPR2, AVPR1B, AVPR1A | AVPR1B 2/4885CYP3A4 3335/4885ALDH1A1 3653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.